Recap: Acrivon Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Acrivon Therapeutics (NASDAQ:ACRV) reported its Q3 earnings, beating estimated earnings by 7.04% with an EPS of $-0.66 versus an estimate of $-0.71. However, revenue was down $0 from the same period last year. Last quarter, the company beat EPS by $0.02, which led to a 6.81% increase in the share price the next day.
November 09, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acrivon Therapeutics beat Q3 earnings estimates, which could lead to a positive impact on its stock price, as seen in the previous quarter when a beat on EPS led to a 6.81% increase in the share price.
Acrivon Therapeutics has reported better than expected earnings for Q3, which is generally a positive signal for investors and can lead to an increase in the stock price. This is further supported by the company's past performance, where a beat on EPS in the previous quarter led to a 6.81% increase in the share price the next day.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100